Quick Answer
Kalaris Therapeutics, Inc. reported R&D Expense of $30.75 million for fiscal year 2025.
Kalaris Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $30.75M | -31.7% |
| 2024 | $45.04M | -66.2% |
| 2023 | $133.07M | +11.9% |
| 2022 | $118.87M | -1.5% |
| 2021 | $120.73M | +143.1% |
| 2020 | $49.66M | +205.7% |
| 2019 | $16.25M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.13M | -74.7% | +8.1% |
| June 30, 2025 | $8.44M | +162.8% | +40.0% |
| March 31, 2025 | $6.03M | +207.5% | -83.3% |
| September 30, 2024 | $36.02M | +5.5% | +35920.0% |
| August 31, 2024 | $100.0K | — | -96.9% |
| June 30, 2024 | $3.21M | -90.8% | +63.7% |
| March 31, 2024 | $1.96M | -93.6% | -94.3% |
| September 30, 2023 | $34.16M | +13.8% | -1.9% |
- Kalaris Therapeutics, Inc. showed a decrease of -31.7% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Kalaris Therapeutics, Inc.’s r&d expense has grown by 89.3% (from $16.25 million to $30.75 million).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: